Filter posts

Discrimination Against Vulnerable Patients Is Nothing New

Transformative therapies are advancing like never before, and a new class of medicines are changing …

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

Just moments after it was announced the FDA had approved a new treatment for spinal …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …

PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine …

Pharmacy Revenues Decline, Thanks to Cheaper Medicines

We’ve been saying it for some time, and the numbers speak for themselves: spending on …

What's Driving Health Care Spending? Hint: Not Drug Costs.

With health care costs an important concern for many Americans, a common misperception is the …

For Today’s Hearing on the Drug Delivery System, ‘Follow The Pill’

The Senate Committee on Health, Education, Labor, and Pensions will hold a hearing this morning …